Aulos Bioscience Reports Promising Phase 1/2 Results for AI-Designed Melanoma Therapy at ASCO 2026
Key Insights
Aulos Bioscience (search) will present promising Phase 1/2 data for imneskibart (AU-007) in checkpoint inhibitor-refractory cutaneous melanoma (search) at the ASCO 2026 Annual Meeting.
Imneskibart is an AI-designed human monoclonal antibody that redirects IL-2 to enhance anti-tumor immune effects while preventing immunosuppression typically associated with IL-2 therapies.
The study evaluated imneskibart combined with low-dose subcutaneous IL-2, with and without nivolumab, in patients who had failed previous checkpoint inhibitor treatments.
Aulos Bioscience (search) announced that promising Phase 1/2 clinical trial data for its lead immune-activating antibody therapeutic imneskibart (AU-007) will be presented at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting. The presentation will focus on results from patients with checkpoint inhibitor (CPI)-refractory cutaneous melanoma (search) treated with imneskibart combined with low-dose subcutaneous IL-2, both with and without nivolumab.
Novel AI-Designed Mechanism of Action
Imneskibart represents a breakthrough in IL-2 therapeutic design, developed using artificial intelligence to target the CD25 (search)-binding portion of IL-2 with high selectivity. The human IgG1 monoclonal antibody employs a mechanism of action unlike any other IL-2 therapeutic currently in development, according to the company.
The therapy works by preventing IL-2—whether administered exogenously or secreted by effector T cells—from binding to trimeric receptors on regulatory T cells, while still allowing IL-2 to bind and expand effector T cells and NK cells. This approach prevents the negative feedback loop typically caused by other IL-2-based treatments and biases the immune system toward activation rather than suppression.
Addressing IL-2 Therapy Limitations
A key advantage of imneskibart is its potential to reduce the severe toxicities associated with traditional high-dose IL-2 therapy. The antibody prevents IL-2 from binding to CD25 (search)-containing receptors on eosinophils, as well as vasculature and pulmonary endothelium, which may significantly reduce the vascular leak syndrome and pulmonary edema that have limited the clinical utility of IL-2 treatments.
Clinical Trial Details
The ongoing Phase 1/2 study (ClinicalTrials.gov identifier: NCT05267626) is being conducted at multiple locations in the United States and Australia. The ASCO presentation will detail results from patients with cutaneous melanoma (search) who had previously failed checkpoint inhibitor therapy, representing a patient population with significant unmet medical need.
ASCO 2026 Presentation
The poster presentation, titled "Imneskibart + low-dose subcutaneous IL-2 ± nivolumab in patients with CPI-refractory cutaneous melanoma (search): Promising results from an ongoing phase 1/2 study," will be presented during the Poster Session - Melanoma/Skin Cancers on Sunday, May 31, 2026, from 9:00 a.m. to 12:00 p.m. CDT. The poster will be available both in the Exhibit Hall at McCormick Place and electronically on the ASCO 2026 online meeting platform.
Company Background
Aulos Bioscience (search) is an immuno-oncology company focused on developing immune-activating antibody therapeutics that direct patients' immune systems toward killing tumor cells. The company was founded through a collaboration between Biolojic Design (search) and Apple Tree Partners (search) (ATP), combining world-class machine learning capabilities with deep understanding of immune system biology. The company's approach matches artificial intelligence-driven antibody design with expertise in cancer immunotherapies to develop novel therapeutic candidates.